前瞻性评估 BRCA1 基因状态在接受 trabectedin 治疗的肉瘤患者中的预测价值：EORTC 62091 试验的更新分析。
Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.
机构信息
Institut Bergonié, Bordeaux, France.
INSERM U1218, Bordeaux, France.
出版信息
Cancer Med. 2018 May;7(5):1575-1577. doi: 10.1002/cam4.1403. Epub 2018 Apr 15.
Abstract
We describe the predictive value of BRCA1 gene status on trabectedin efficacy and found no correlation despite the mechanisms of action of this drug that rely on DNA repair systems.
摘要
我们描述了 BRCA1 基因状态对 trabectedin 疗效的预测价值，但尽管该药物的作用机制依赖于 DNA 修复系统，但并未发现相关性。
Zotero 插件